Introduction: To evaluate the efficacy and safety of PreserFlo Ò MicroShunt in primary open angle glaucoma (POAG) eyes after a single failed trabeculectomy. Methods: Retrospective review of POAG eyes with a failed trabeculectomy that underwent PreserFlo Ò MicroShunt implantation from March 2019 to November 2019, in two Italian glaucoma centers. Pre-and postoperative data were collected and compared. Results: A total of 31 surgeries in 31 patients were reviewed. Mean preoperative IOP and mean preoperative number of medications were 24.12 ± 3.14 mmHg and 3.29 ± 0.64, respectively, and decreased to 12.56 ± 2.64 mmHg and 0.46 ± 0.77 at the 12-month postoperative follow-up visit (p \ 0.01). The most frequent adverse events were transient hypotony (6 eyes, 19.3%) and choroidal effusion (3 eyes, 9.6%). In all cases spontaneous resolution was observed, with no intervention.
Conclusion:In POAG eyes with a single failed trabeculectomy, the PreserFlo Ò MicroShunt was safe and effective in reducing the IOP after a 12-month follow-up. The PreserFlo Ò Micro-Shunt may represent a viable choice as a second surgery.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.